Laurentiu Agrigoroaie

Laurentiu Agrigoroaie

Auto-generated profile, based on publicly available information

Laurentiu Agrigoroaie

Medical Imaging Department Gustave Roussy Villejuif France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2021 in ACS Applied Nano Materials
Verified
Journal Article
Closed access
BDBrindusa Dragoi
Brindusa Dragoi
Cristina Mariana UrituCristina Mariana Uritu
Cristina Mariana Uritu
LALaurentiu Agrigoroaie
Laurentiu Agrigoroaie
DLDoina Lutic
Doina Lutic
VHVasile Hulea
Vasile Hulea
ECEugen Carasevici
Eugen Carasevici

14 February 2025 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
LALaurentiu Agrigoroaie
Laurentiu Agrigoroaie
NANadege Anizan
Nadege Anizan
CGCamilo Garcia
Camilo Garcia
CBCorinne Balleyguier
Corinne Balleyguier
THThéophraste Henry
Théophraste Henry
Device-based respiratory gating improves diagnostic and quantification accuracy in positron emission tomography (PET), but requires additional time to setup the device and the failure rate can be significant. Our aim was to internally validate the quantification performance of data-driven respiratory-gated PET imaging against the gold standard, the device-based method, in clinical oncological practice. We retrospectively analysed [18F]FDG PET/CT scans of patients from our centre with at least one measurable [18F]FDG-avid malignant lesion. All PET/CT acquisitions were performed on a Siemens Biograph 64 Vision 600 system with respiratory gating by belt and also by adding the data-driven gating with OncoFreeze AI™. We recorded the SUVmax and SUVpeak for up to a maximum of 5 lesions per patient. We computed the mean absolute bias between the two gating methods and the 95% confidence intervals (CI) at the cohort level and in subgroups. Of the 692 consecutive patients screened for inclusion, 196 patients were analysed, from whom 536 lesions were measured. The mean absolute biases in the SUVmax and SUVpeak of lesions in the whole cohort were 3.8% (CI 3.4–4.2) and 2.1% (CI 1.9–2.4), respectively. At patient-level, 21% of them had at least one lesion with a SUVmax bias above 10%, while for SUVpeak this proportion was 5%. In the subgroup analysis by PERCIST criteria, only 2% of patients had significant bias in the SUVmax, and 0.5% in SUVpeak. There was no clinically significant effect of lesion size or anatomical site on SUV measurements between the two respiratory gating methods. Quantitative comparison of data-driven and device-based respiratory-gated PET scans revealed negligible differences, proving that data-driven respiratory gating is a reliable and accurate alternative to the device-based gating method in routine [18F]FDG-PET/CT oncological evaluation.

23 September 2026 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
GSGiovanni Spinaci
Giovanni Spinaci
LALaurentiu Agrigoroaie
Laurentiu Agrigoroaie
DODaniel Orbach
Daniel Orbach
SMSalma Moalla
Salma Moalla
HBHelene Boutroux
Helene Boutroux
NJNina Jehanno
Nina Jehanno

8 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
ADAlessia Lucia Daverio
Alessia Lucia Daverio
ACAlessandro Coccarelli
Alessandro Coccarelli
THThéophraste Henry
Théophraste Henry
ADAlina Danu
Alina Danu
LALaurentiu Agrigoroaie
Laurentiu Agrigoroaie
Desiree DeandreisDesiree Deandreis
Desiree Deandreis
Background/Objectives: Multiple myeloma (MM) is a complex hematologic malignancy characterized by abnormal plasma cell proliferation in the bone marrow. [18F]FDG PET/CT has emerged as a key imaging modality, demonstrating high sensitivity and specificity for the detection of metabolically active disease compared with conventional imaging techniques. This review examines the role of PET/CT imaging in evaluating therapeutic response in symptomatic myeloma, including minimal residual disease (MRD) assessment. Methods: We surveyed the literature published between 2014 and 2024 across PubMed, Scopus, Web of Science, and the Cochrane Library for peer-reviewed articles evaluating PET imaging in the assessment of treatment response in multiple myeloma. Results: [18F]FDG PET/CT provides a whole-body assessment of disease burden, extramedullary involvement detection, and early metabolic response evaluation. Standardized response assessment criteria (Deauville, IMPeTUs, IMWG) have enhanced the reproducibility and accuracy of treatment monitoring. Semiquantitative parameters including SUVmax and metabolic tumor volume (MTV) provide useful prognostic information with PET negativity correlating with improved progression-free and overall survival. The integration of PET/CT with bone marrow assessment techniques (next-generation flow cytometry and sequencing) optimizes MRD evaluation and patient stratification. Conclusions: PET/CT represents a valuable imaging tool for improving therapeutic decision making and risk stratification in MM management. Emerging radiotracers beyond FDG, including [11C]choline, [11C]methionine, and targeted agents like [68Ga]pentixafor and CD38-targeted immunoPET tracers, hold promise for enhanced diagnostic capabilities in specific clinical contexts.

2 March 2026 in Clinical Nuclear Medicine
Verified
Journal Article
Open access
ABAdam Bekkhoucha
Adam Bekkhoucha
LALaurentiu Agrigoroaie
Laurentiu Agrigoroaie
Desiree DeandreisDesiree Deandreis
Desiree Deandreis
DGDavid Guyon
David Guyon
FCFeras Chehade
Feras Chehade
Metastases from meningioma are very rare and occur predominantly in WHO grade II and III tumors, with the lungs being the most common site. The increasing use of 68 Ga-DOTA-peptides PET/CT has improved the detection of primary and secondary tumor sites. This imaging modality, evaluating the tumor expression of somatostatin receptors (SSTR), not only refines the diagnostic accuracy but also can guide a subsequent peptide receptor radionuclide therapy (PRRT). We report a case of meningioma brain tumor becoming refractory after initial neurosurgery and stereotactic radiotherapy. Meningioma has progressed to lung metastases displaying high expression of SSTR, and hence suitable for PRRT.